The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
It's that time again! Jim Cramer rang the lightning round bell, which means he gave his take on caller favorite stocks at rapid speed:
Osiris Therapeutics: "Osiris is a very real company, down a lot like a lot of these, but still up for the year...the regeneration of human tissue I think is an exciting spec. The emphasis is on spec, but remember Celgene has come down a lot, too, and I like those."
Opko Health Inc: "I thought that [CEO] Dr. Phil Frost, when he came on, acquitted himself well...and I think this stock is a buy right here, right now. I'm not afraid to stick my neck out for Phil Frost. He has made so much money for people."
Himax Technologies: "I think it will be forever flat. There's really not much there. Even when Maxim is talking about merging with Analog Devices, when we are hearing about Fairchild for sale — this thing doesn't move. What does that tell you? It says you don't want a part of it."
Read more from Mad Money with Jim Cramer
PPG Industries: "PPG reports tomorrow. Now here's what we know about PPG other than how great Chuck Bunch who is now chairman. This stock went all the way down to $82. It has bounced back to the mid $90s. I wish it weren't so high because these stocks I think are still for sale because we are overbought. But PPG, you're not going to go wrong if you buy this stock in the low $90s. So I'm going to say buy buy buy after it reports pick some up. It tends to get hit at that moment when it reports."
Icon PLC: "Clinical research? You know that we are Quintiles people here. We are not going to change our mind. We are sticking with the letter Q."
Rite Aid: "Rite Aid has been a one way ticket down. I recognize that ever since that last same-store sales month. It has to be able to put two good same-store sales numbers together before it starts rallying again. That doesn't mean I'm abandoning it, if anything it means I'm buying it."